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The main causes of morbidity and mortality in diabetes are
macrovascular and microvascular complications. The pathogen-
esis of these complications is multifactorial, but there is strong
evidence implicating chronic, smoldering, and inflammation as
a main pathogenic event in the development of diabetic compli-
cations (1). Although the mechanisms responsible for vascular
inflammation in diabetes are similar to those involved in vas-
cular disease in non-diabetics (2), chronic hyperglycemia and
dysregulated immune responses in diabetes are responsible for
the activation of inflammatory circuits, inducing oxidative stress
and promoting insulin resistance (1, 3), thus creating conditions
that lead to the development of diabetes and diabetic complica-
tions. Changes in gene expression associated with diabetes like
increased ICAM-1 expression (4) may also play a role in inducing
inflammation and the development of diabetic complications.
Increased expression of adhesion molecules is associated with
the development of diabetic complications. As discussed by Gu
et al. (5), over-expression of ICAM-1, may be one of the key
events in the development of nephropathy, as reflected by signifi-
cant correlations between ICAM-1 levels and the development of
proteinuria. Although the increased expression of ICAM-1 is not
exclusive of diabetes, a linkage of the ICAM-1 gene to diabetes and
diabetic nephropathy (5) suggests a selective involvement of this
particular inflammatory event in both type 1 and type 2 diabetes.
Clinically, ICAM-1 and other adhesion molecules like E-selectin
can predict development of diabetic nephropathy and perhaps
other complications in type 1 diabetes (5). Therapeutically, exper-
imental data suggest that inhibiting ICAM-1 gene expression may
prevent or slow down the development of diabetic nephropa-
thy (5). As uncontrolled chronic inflammation progresses, kidney
fibrosis develops, leading to end-stage kidney disease. Recruitment
and activation of macrophages and of CD4+ T cells after initial
tissue injury precede and have a critical role in the development
of fibrosis, thus linking inflammation to the development of renal
fibrosis (6). Several drugs used in the treatment of renal insuf-
ficiency have anti-inflammatory properties. However, the use of
anti-inflammatory agents has not been effective in the treatment of
diabetic nephropathy (6), likely because, once the fibrotic process
becomes irreversible, the value of such interventions is limited.
Oxidation and other forms of modification of lipids and
lipoproteins have emerged as a major pathogenic factor in athero-
sclerosis. Modified lipoproteins deliver pro-inflammatory signals
that activate innate and adaptive immune responses and disturb
the integrity of the microvasculature (3). In diabetes, the com-
bination of hyperglycemia and increased oxidative stress results
in enhanced LDL modification. Advanced glycation end-products
(AGE)-modified LDL plays an important pathogenic role through
its interactions with RAGE and angiotensin receptors (3). Oxidized
LDL activates T cells, leading to enhanced inflammation through
the release of macrophage-activating mediators (2). The adaptive
humoral autoimmune response to modified forms of LDL is well
characterized and strong evidence exists linking the formation of
immune complexes (IC) involving modified forms of LDL and
the corresponding autoantibodies with the development of dia-
betic complications. High levels of oxidized LDL in IC strongly
predict the progression of atherosclerosis in patients with type 1
diabetes, while high levels of malondialdehyde-modified LDL in
IC indicate strong risk for acute cardiovascular events in patients
with type 2 diabetes (7).
Modified LDL molecules express a variety of immunogenic epi-
topes. The most immunogenic and better characterized are modi-
fied lysine epitopes, but oxidized phospholipids are also exposed to
the immune system (2). Phosphorylcholine is a particularly inter-
esting epitope because the resulting antibodies appear to protect
against the development of atherosclerosis (2). Because phospho-
lipid autoantibodies are usually of the IgM isotype, their protective
effect could be a result of the reduced inflammatory poten-
tial of IgM IC, which cannot activate phagocytic cells through
Fc receptors. Therefore, the end result of the humoral immune
response to modified LDL could depend on which antibodies pre-
dominate: the strongly pro-inflammatory IgG antibodies or the
non-inflammatory IgM antibodies.
There is a large diversity of autoantibodies, besides those
directed to modified LDL and phospholipids that are believed to
play a pathogenic role in diabetes. To that long list,Zimmering et al.
added anti-neurotrophic antibodies, which seem to be involved
in the pathogenesis of open-angle glaucoma and/or dementia in
adult diabetics (4).
There is great interest in defining biomarkers predictive of
diabetic complications. Among the many biomarkers that have
been proposed, the blood levels of ICAM-1 (5), the levels of
modified LDL in circulating IC (7), and the levels of fibroblast
growth factor (8) are discussed in this e-book. While ICAM-1 lev-
els and its polymorphisms appear linked to the development of
nephropathy, the levels of modified LDL in IC and the levels of
fibroblast growth factor have predictive value for cardiovascular
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disease in type 1 and type 2 diabetes. The results are quite
strong since they were based on data obtained on a large number
of patients.
As evidence supporting the pathogenic role of the adaptive
immune response in diabetes accumulates, there has been a surge
in the investigation of down-regulatory mechanisms that could be
therapeutically exploited. The role of T regulatory (Treg) cells has
been the object of considerable attention. Data generated in ani-
mal models suggest that Treg cells play a critical role in controlling
the development of diabetes, both in type 1 and type 2 models (9).
Also in animal models, there is data suggesting that administration
of CD3 monoclonal antibodies permanently reverses diabetes in
NOD mice. In humans, the results have not been so spectacular,
but in type 1 diabetic patients CD3 antibody administration seems
to preserve islet cell function for 1–5 years (9). Although human
trials have never replicated the animal model data, the data remain
very appealing.
A second alternative, also suggested by data in animal models,
is to enhance the regulatory effect on incretin hormones, particu-
larly glucagon-like peptide-1 (GLP-1) whose levels or effects can
be enhanced by the administration of GLP-1 receptor agonists, or
by inhibitors of dipeptidyl peptidase (DDP)-4, and enzyme that
degrades GLP-1 (10). Data obtained in mice suggest that GLP-1 has
modulatory effects, promoting the survival of Treg cells, and treat-
ment with incretins suppresses the progression of atherosclerosis
(10). Whether the administration of GLP-1R agonists or DDP-4
inhibitors may have similar effects in humans is a very interesting
concept and worth investigating.
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